Parental Report of Medication Acceptance Among Youth: Implications for Everyday Practice

Polaha, Jodi; Dalton, William T.; Lancaster, Blake M.

doi:10.1097/smj.0b013e318180645d

Cited by 42 publications

(42 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This difference was less pronounced for capsules (20.1% and 36.5% respectively). Similar rates of prior use have been reported elsewhere, including a US survey which found that nearly all 165 respondents aged 12 years and over had used SODFs in the past (Polaha et al, 2008).…”

Section: Tablets and Capsulessupporting

confidence: 62%

“…Nevertheless, evidence has shown that children as young as 3 years old are able to swallow conventional tablets and capsules (Nahirya-Ntege et al, 2012, Kaplan et al, 2010, Czyzewski et al, 2000. On the other hand, older children and adolescents have reported swallowing difficulties, including as a barrier to adherence in chronic conditions (Hansen et al, 2008, Polaha et al, 2008, Hommel and Baldassano, 2010, Modi et al, 2013. The present study highlights 185 that while age is a critical factor, other aspects such as health background are also important characteristics to consider.…”

Section: Tablets and Capsulesmentioning

confidence: 83%

See 1 more Smart Citation

Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study

Ranmal¹,

Cram

Tuleu³

2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

A lack of evidence to guide the design of age-appropriate and acceptable dosage forms has been a longstanding knowledge gap in paediatric formulation development. The Children's Acceptability of Oral Formulations (CALF) study captured end-user perceptions and practices with a focus on solid oral dosage forms, namely tablets, capsules, chewables, orodispersibles, multiparticulates (administered with food) and mini-tablets (administered directly into the mouth). A rigorous development and testing phase produced age-adapted questionnaires as measurement tools with strong evidence of validity and reliability. Overall, 590 school children and adolescents, and 428 adult caregivers were surveyed across hospitals and various community settings. Attitudes towards dosage forms primarily differed based on age and prior use. Positive attitudes to tablets and capsules increased with age until around 14 years. Preference was seen for chewable and orodispersible preparations across ages, while multiparticulates were seemingly less favourable. Overall, 59.6% of school children reported willingness to take 10mm diameter tablets, although only 32.1% of caregivers perceived this size to be suitable. While not to be taken as prescriptive guidance, the results of this study provide some evidence towards rational dosage form design, as well as methodological approaches to help design tools for further evaluation of acceptability within paediatric studies.

show abstract

Section: Tablets and Capsulessupporting

confidence: 62%

Section: Tablets and Capsulesmentioning

confidence: 83%

Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study

Ranmal¹,

Cram

Tuleu³

2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…In 2008, a survey was done of 304 parents with children aged 0 to 26 years. 1 This survey found that 30% to 40% of parents had children who rejected or refused a pill or liquid medication, and .50% had children who were unable to swallow a standard size pill or small capsule. 1 The majority of the children in the survey were otherwise healthy, with only 10.9% documented to have a chronic illness.…”

mentioning

confidence: 99%

“…1 This survey found that 30% to 40% of parents had children who rejected or refused a pill or liquid medication, and .50% had children who were unable to swallow a standard size pill or small capsule. 1 The majority of the children in the survey were otherwise healthy, with only 10.9% documented to have a chronic illness. 1 Other studies have found that struggles in pill swallowing can extend into adolescence and can have significant detrimental effects for those with chronic illnesses.…”

mentioning

confidence: 99%

“…1 The majority of the children in the survey were otherwise healthy, with only 10.9% documented to have a chronic illness. 1 Other studies have found that struggles in pill swallowing can extend into adolescence and can have significant detrimental effects for those with chronic illnesses. 2,3 In 2008, Hansen et al 2 interviewed 89 healthy adolescents aged 11 to 20 years about their struggles with swallowing tablets.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of Pediatric Pill Swallowing Interventions: A Systematic Review

et al. 2015

View full text Add to dashboard Cite

show abstract

Drug Regimen Individualization for Attention‐Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations

et al. 2018

View full text Add to dashboard Cite

In 2000, the first biphasic modified-release (MR) formulation of methylphenidate (MPH) was approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). An immediate-release (IR) MPH pulse (22% of the dose) facilitates rapid onset of stimulant action, while the remaining MR portion of the dose provides for day-long duration of efficacy. A wide array of oral MR-MPH products has subsequently been approved that also allows for once-daily dosing, though each product is characterized by distinctive exposure time courses. This review compares each member of the current MPH armamentarium to assist in the rational selection of a specific MPH regimen for the individualized treatment of patients with ADHD. The IR portion of biphasic MPH formulations now ranges from 15%, 20%, 22%, 25%, 30%, and 37% IR-MPH, as well as a 50% IR-MPH product whose distinctly pulsatile time course closely resembles that of the pre-century "gold standard" twice-daily IR-MPH regimen. Further, transdermal, suspension, and orally disintegrating tablet products are now available to overcome any solid dosage form swallowing difficulties. Most of these formulations are racemic, though in 2001, a chiral switch drug IR-dexmethylphenidate (dexMPH) was approved, followed by biphasic MR-dexMPH (50% IR) in 2005. New U.S. Food and Drug Administration (FDA) partial area under the curve (pAUC) bioavailability metrics have improved discrimination between specific generic MR-MPH products. This has resulted in two Orange Book MR-MPH products being recoded from "AB" (i.e., meets necessary bioequivalence requirements) to "BX" (i.e., insufficient data to confirm bioequivalence). The metabolic drug interaction between MPH and alcohol, which increases MPH bioavailability, potentiates euphoric effects, and heightens abuse liability, is discussed. This review concludes with brief considerations of pharmacogenomic predictors of ADHD first-line drug selection, carboxylesterase allelic variants influencing interindividual MPH metabolism, and novel MPH formulations in the regulatory pipeline. KEY WORDS methylphenidate, dexmethylphenidate, attention-deficit/hyperactivity disorder, pharmacokinetics, partial area under the curve, early exposure, relative bioavailability, carboxylesterase 1, bioequivalence.Estimates of attention-deficit/hyperactivity disorder (ADHD) global prevalence generally range from 5% to 7% in the pediatric population. 1,2 Recognition that ADHD often persists into adulthood has become well established, a

show abstract

Parental Report of Medication Acceptance Among Youth: Implications for Everyday Practice

Abstract: The results provide directions for future research as well as the translation of pill swallowing interventions to primary care.

Cited by 42 publications

References 16 publications

Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study

Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study

Effectiveness of Pediatric Pill Swallowing Interventions: A Systematic Review

Drug Regimen Individualization for Attention‐Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations

Contact Info

Product

Resources

About